Estados financieros detallados de Context Therapeutics Inc. (CNTX): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $0.38, CNTX presenta beneficios negativos (P/E no significativo) y un ROE del -82.06%. La capitalización bursátil es de $35M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Bruto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| I+D | $2.4M | $1.6M | $3.8M | $7.1M | $17.8M | $22.7M | $31.9M |
| Generales y Administrativos | $3.0M | $930667 | $3.6M | $7.8M | $7.3M | $7.2M | $7.8M |
| Gastos Operativos | $5.4M | $2.6M | $10.5M | $15.4M | $25.1M | $29.9M | $39.7M |
| Beneficio Operativo | -$5.4M | -$2.6M | -$10.5M | -$15.4M | -$25.1M | -$29.9M | -$39.7M |
| EBITDA | -$5.4M | -$2.6M | -$10.5M | -$14.9M | -$24.0M | -$26.7M | -$36.1M |
| Gastos por Intereses | $1.1M | $661224 | $64240 | $547268 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$6.4M | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$6.4M | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| BPA | $-0.68 | $0.10 | $-3.69 | $-0.93 | $-1.50 | $-0.46 | $-0.38 |
| BPA Diluido | $-0.68 | $0.10 | $-3.69 | $-0.93 | $-1.50 | $-0.46 | $-0.38 |
| Acciones en Circulación (Diluidas) | $11.0M | $11.0M | $2.8M | $16.0M | $16.0M | $58.4M | $95.2M |
Cuenta de Resultados (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Ingresos | 0 | 0 | 0 | 0 |
| Beneficio Bruto | -$4066 | 0 | 0 | 0 |
| Beneficio Operativo | -$10.6M | -$13.8M | -$9.3M | -$15.0M |
| EBITDA | -$9.7M | -$13.0M | -$8.6M | -$14.6M |
| Beneficio Neto | -$9.7M | -$13.0M | -$8.7M | -$14.6M |
| BPA | $-0.10 | $-0.14 | $-0.09 | $-0.15 |
| BPA Diluido | $-0.10 | $-0.14 | $-0.09 | $-0.15 |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Caja y Equivalentes | $226603 | $341037 | $49.6M | $35.5M | $14.4M | $94.4M | $66.0M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $239607 | $349709 | $51.3M | $37.9M | $16.0M | $97.9M | $68.4M |
| Inmovilizado Material | 0 | 0 | 0 | $79535 | $15524 | $230775 | $140066 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Totales | $273548 | $467340 | $51.3M | $38.0M | $16.1M | $98.1M | $68.5M |
| Cuentas por Pagar | $2.1M | $2.7M | $1.8M | $936330 | $2.4M | $1.5M | $2.5M |
| Deuda a Corto | $21.8M | $5.9M | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $24.1M | $9.5M | $3.0M | $3.2M | $4.2M | $2.7M | $8.0M |
| Deuda a Largo | 0 | $69040 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $24.2M | $17.4M | $3.0M | $3.2M | $4.2M | $2.9M | $8.0M |
| Reservas | -$25.4M | -$18.8M | -$29.3M | -$44.1M | -$68.1M | -$94.8M | -$130.9M |
| Patrimonio Neto | -$24.0M | -$16.9M | $48.3M | $34.8M | $11.9M | $95.3M | $60.5M |
| Deuda Total | $21.8M | $6.0M | 0 | $55078 | 0 | $219380 | $112064 |
| Deuda Neta | $21.6M | $5.6M | -$49.6M | -$35.4M | -$14.4M | -$94.2M | -$65.9M |
| Capital Circulante | -$23.9M | -$9.2M | $48.2M | $34.6M | $11.9M | $95.1M | $60.3M |
Balance (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Caja y Equivalentes | $76.9M | $66.0M | $54.5M | $43.0M |
| Activos Totales | $79.2M | $68.5M | $58.9M | $46.1M |
| Pasivos Totales | $6.1M | $8.0M | $6.7M | $8.0M |
| Patrimonio Neto | $73.2M | $60.5M | $52.2M | $38.2M |
| Deuda Total | $140200 | $112064 | $282424 | $244992 |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Beneficio Neto | -$6.4M | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| Amortizaciones | 0 | 0 | 0 | $9268 | $12044 | $10881 | $16251 |
| Compensación en Acciones | $775255 | $219245 | $511079 | $976440 | $1.1M | $841867 | $1.3M |
| Cambio en Capital Circulante | $561791 | $1.3M | -$2.2M | -$277524 | $1.8M | -$3.5M | $6.3M |
| Flujo de Caja Operativo | -$2.8M | -$1.0M | -$8.8M | -$13.5M | -$21.0M | -$14.6M | -$26.4M |
| Inversiones (CapEx) | 0 | 0 | -$250000 | -$536836 | 0 | -$14.8M | -$33948 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$2.8M | -$1.0M | -$9.0M | -$14.1M | -$21.0M | -$29.3M | -$26.4M |
Flujo de Caja (Trimestral)
| Año | 2025-Q3 | 2025-Q4 | 2026-Q1 | 2026-Q2 |
|---|
| Flujo de Caja Operativo | -$6.6M | -$8.9M | -$11.4M | -$7.0M |
| Inversiones (CapEx) | 0 | -$5 | -$37256 | -$18488 |
| Flujo de Caja Libre | -$6.6M | -$8.9M | -$11.5M | -$7.0M |
| Dividendos Pagados | 0 | 0 | 0 | 0 |
| Compensación en Acciones | $323081 | $325168 | $409220 | $528102 |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| Crecimiento Beneficio Neto (anual) | | +204.1% | -257.4% | -41.9% | -61.5% | -11.5% | -35.2% |
| Crecimiento BPA (anual) | | +114.7% | -3790.0% | +74.8% | -61.3% | +69.3% | +17.4% |
| Cambio en Acciones (anual) | | -0.0% | -74.1% | +463.4% | +0.0% | +265.9% | +62.9% |
| Crecimiento FCF (anual) | | +63.5% | -774.7% | -55.7% | -49.4% | -39.3% | +9.9% |
| Tasa Impositiva Efectiva | -0.0% | 0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| FCF por Acción | $-0.26 | $-0.09 | $-3.19 | $-0.88 | $-1.32 | $-0.50 | $-0.28 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $11.0M | $11.0M | $2.8M | $16.0M | $16.0M | $58.4M | $95.2M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -82.06% |
| Rentabilidad sobre capital invertido | -126.84% |
| Rentabilidad sobre activos | -99.62% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.01 |
| Ratio corriente | 5.81 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 6.94 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|
| P/E | -7.50 | 51.00 | -0.72 | -0.70 | -0.75 | -2.28 | -3.87 |
| P/VC | -2.33 | -3.30 | 0.16 | 0.30 | 1.52 | 0.64 | 2.31 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |